Sunday, September 13, 2020 10:39:44 PM
Does that mean I can use Lysol off label? Somewhere I heard that might also be an option for treating my COVID infection; not sure where I heard it, but someone said it might, but not sure who? :)
Seriously, the question is first, does a biologic fall under the same general regs for off label use as a drug? And second, since D and L are administered differently and the tumor tissue is different (Ex’s argument), wouldn’t this somehow be a different approval process?
For instance, in terms of safety, how do we know sarcomas react the same way as GBM cancer cells? In some way, by pulsing dendritic cells from different tumor types, in effect, is that creating a different type of vaccine?
Also, would a BP pay for an unproven off label indication? Would doctors and their insurance carriers be skittish about malpractice exposure?
By the way, at my first ASM I spoke with a clinician who took part in the colon cancer (if I recall correctly?) trial, and she was almost certain that the vaccine works for that indication. Of course she was blinded, so could not know for sure.
Seriously, the question is first, does a biologic fall under the same general regs for off label use as a drug? And second, since D and L are administered differently and the tumor tissue is different (Ex’s argument), wouldn’t this somehow be a different approval process?
For instance, in terms of safety, how do we know sarcomas react the same way as GBM cancer cells? In some way, by pulsing dendritic cells from different tumor types, in effect, is that creating a different type of vaccine?
Also, would a BP pay for an unproven off label indication? Would doctors and their insurance carriers be skittish about malpractice exposure?
By the way, at my first ASM I spoke with a clinician who took part in the colon cancer (if I recall correctly?) trial, and she was almost certain that the vaccine works for that indication. Of course she was blinded, so could not know for sure.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
